Email: Password:
| Forgot Password
Nav_logo

A free online accredited CPD program for healthcare professionals

Getting to Target Safely: Newer long-acting basal insulin analogues for managing type 2 diabetes (T2D)

1.00 Canadian Council On Continuing Education In Pharmacy (CCCEP) CEU(s) / 1.00 Ordre des pharmaciens du Québec (OPQ) CEU(s)

Program available online until: September 11, 2018



This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP)
for 1.00 CEU(s).

This continuing education activity has been accredited by l'Ordre des Pharmaciens du Quebec, which will grant 1.00 CEU(s) to pharmacists who have completed it successfully.

T2D and newer long-acting basal insulins

/Content/Programs/CaseStudy/T2D_Management_10889/assets/images/GettyImages-508214066.jpg

An estimated 3.65 million Canadians have type 2 diabetes. The goal in treating patients with diabetes is to get them to target as quickly as possible, ideally within 3-6 months, while avoiding hypoglycemia. This may often involve adding or switching medications, including intensifying treatment using insulin.

Basal insulins are used to control blood sugar levels when fasting (especially overnight) and between meals. An ideal basal insulin would have the following properties: a flat glucose-lowering profile, a stable rate of absorption, and minimal variability. Newer, long-acting insulins, such as insulin degludec (IDeg) and insulin glargine 300 U/mL (IGlar 300), offer patients options for more stable control of diabetes with low risk of hypoglycemia.

This program will focus on T2D and newer long-acting basal insulins, and their impact on diabetes control and hypoglycemia.

Planning Committee

  • Peter Senior, BMedSci, MBBS, PhD, FRCP(E), FRCP.
  • Robert S. Roscoe, BSc. Pharm, ACPR, CDE, CPT.
  • Michael Boivin, BSc Pharm.

Learning Objectives

After completion of the program, participants will be able to:

  1. Define the key targets for patients with type 2 diabetes;
  2. Address misconceptions around hypoglycemia in patients with type 2 diabetes taking insulin;
  3. Describe the general characteristics of long acting/ultra long acting basal insulins.
  4. Discuss the ability of newer long-acting insulins, to control blood glucose in type 2 diabetes and their impact on the risk for hypoglycemia.

Questions answered by our expert:
Michael Boivin, BSc Pharm, RPh, CDE, CTE, CTH

  1. At what point should patients with T2D be started on insulin?
  2. What is the role of the pharmacist for patients starting on insulin?
  3. What are some of the factors to consider when discussing insulin options with your patients with diabetes?
  4. When is it appropriate to switch from one long-acting insulin to another?
  5. How do you counsel someone on basal insulin who is experiencing hypoglycemia?
  6. In what situations should primary care clinicians refer patients with diabetes to a specialist?
  7. How do you counsel type 2 patients who are resistant to starting on insulin therapy?
/Content/Programs/CaseStudy/T2D_Management_10889/assets/images/MBoivin.jpg

mdBriefCase is the practical choice to earn your CPD Credits

Icon of multiple pages

20+ therapeutic areas

100+ programs each year.

Icon of multiple pages

Quality, accredited content

Developed by leading specialists and peer-reviewed by experts at respected institutions.

Icon of multiple pages

Online convenience

Save time and money.

Join 45,000+ of your colleagues

Create your free account today